Congratulations to Dr Guillaume CARRIER who has received an award from the Biocodex Microbiota Foundation for the MICARE project!

Je suis un bloc de texte, cliquez sur le bouton \”éditer\” pour me modifier. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Dr. Guillaume CARRIER completed his thesis on the prognostic impact of the microbiota in the survival of patients with colorectal cancer. Thanks to his work, he was able to demonstrate a link between the colonization of the microbiota by certain pathogenic strains and 5-year survival. Among these pathogenic strains, Escherichia coli producing colibactin (CoPEC), a genotoxin, was more particularly studied.
Dr. Guillaume CARRIER initiated the MICARE study, currently promoted by Pr Philippe ROUANET at the ICM. The goal of this project is to determine, in a non-invasive manner (stool samples), a correlation between colonization by these strains of pathogenic bacteria (CoPEC) and the response to neoadjuvant treatment by radiochemotherapy, in patients with rectal cancer.
The results of this study could lead to a better understanding and selection of patients for personalized treatment in rectal cancer. If a correlation is demonstrated, these patients carrying these pathogenic strains could therefore in practice receive an intensified neoadjuvant treatment being less responsive to radiotherapy.
The study started in January 2020, with the inclusion of 11 patients over 2 months, but was stopped due to COVID 19. Inclusions have since resumed and it is hoped to reach the 220 patients included by November 2022 as originally planned.
This work was supported by SIRIC Montpellier cancer in 2019-2020 as part of the thesis of Dr Guillaume CARRIER. The grant awarded by the Biocodex Microbiota Foundation will complement the SIRIC funding for the analysis of samples performed by Dr. Mathilde BONNET at the M2iSH laboratory (INSERM and Clermont Auvergne University).